i2 Pharmaceuticals, Inc.a biopharmaceutical company focused on next generation discovery and development of therapeutics with a focus on personalized cancer treatment, announced the appointment of David Stover, Ph.D., as Chief Executive Officer, effective July 1, 2018. Dr. Stover brings to i2 over 25 years of experience in both small-molecule and biologics drug discovery and development.
| BOULDER, Colo. /PRNewswire/ --i2 Pharmaceuticals, Inc. a biopharmaceutical company focused on next generation discovery and development of therapeutics with a focus on personalized cancer treatment, announced the appointment of David Stover, Ph.D., as Chief Executive Officer, effective July 1, 2018. Dr. Stover brings to i2 over 25 years of experience in both small-molecule and biologics drug discovery and development. “Dave is an accomplished pharmaceutical researcher and scientist with considerable experience in the development of novel antibody-based therapeutics,” stated Bruce Eaton, Ph.D., i2’s Chairman of the Board. “We are extremely pleased to have Dave at the helm of the Company as we enter a strategic growth-phase driving our new business opportunities in antibody therapeutics.” Dr. Stover commented, “I am excited for this opportunity and look forward to working with the i2 team, Board members and advisors as we seek to optimize the value of the Company’s unique and proprietary suite of transformative technologies and assets. Our goal at i2 is to leverage the breadth of i2’s cutting edge discovery technologies to develop new novel-antibody based therapeutics.” Prior to joining i2 Pharma, Dr. Stover was most recently head of Agensys, Inc., an Astellas Pharma affiliate focused on antibody and antibody drug conjugate development, where he led a team of 240 employees in the research, clinical manufacturing and development of five investigational new drugs and four clinical proof of concepts during a 5-year period. Dr. Stover also founded the Oncology Biologics department at Novartis, where he served as its director, developing three clinical product candidates. Previously, he held the position of vice president of drug discovery at MDS Proteomics, where he managed research sites in Cambridge, MA, Charlottesville, VA and Toronto. Earlier in his career, Dr. Stover was the first employee and director of biochemistry at Kinetix Pharmaceuticals, a small-molecule kinase inhibitor company that was acquired by Amgen in 2000. Dr. Stover earned his Ph.D. in Biochemistry at the University of Washington and holds a Bachelor of Science degree in Zoology from Duke University. About i2 Pharmaceuticals i2 Pharmaceuticals is a biopharmaceutical company focused on next generation discovery and development of therapeutics with a focus on cancer treatment. i2 is unique in that it generates its pipeline of product candidates from its proprietary suite of transformative technologies particularly in antibody discovery and engineering approaches. We are innovators coupling the power of cutting edge discovery technologies, proprietary Ab formats, and a deep understanding of molecular oncology and Immuno-oncology to accelerate the development of more effective and safer therapeutics. For more information please visit i2pharma.com.
View original content:http://www.prnewswire.com/news-releases/i2-pharmaceuticals-appoints-dr-david-stover-as-chief-executive-officer-300695068.html SOURCE i2 Pharmaceuticals, Inc. |
